Vital Therapies (NASDAQ: VTL) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33).

“This is an exciting time for the Company. We are diligently working toward database lock for VTL-308 and expect to report topline results in the second half of September,” said Russell J. Cox, the Company’s Chief Executive Officer. “Additionally, we continue with preparations for the potential submission of a biologics license application and commercial launch of ELAD.”

For earnings history and earnings-related data on Vital Therapies (VTL) click here.